Formycon Raises Fresh Capital To Drive Biosimilar Development
Funding For COVID-19 Also Received
Executive Summary
German biosimilars firm Formycon has raised tens of millions of euros through an issue of new shares, with the cash earmarked for its burgeoning pipeline of wholly-owned biosimilars, including a Lucentis (ranibizumab) candidate being developed with Coherus.